CTNNB1 Connect and Cure Grant Program

CTNNB1 Connect and Cure Grant Program

Funder: CTNNB1 Connect and Cure Inc (NJ, US)

Geographic Scope: No geographic restrictions mentioned; accepts applications from academic, government, non-profit or for-profit research entities

Program Overview

CCC supports several research initiatives per year to advance the understanding and treatment of CTNNB1 Syndrome. Proposals are invited on a rolling basis and may also be solicited in response to specific Requests for Proposals (RFP).

Focus Areas

• Primary interest: Projects that will lead to new interventions to alleviate symptoms associated with CTNNB1 Syndrome
• Accepted areas: All areas of research relevant to CTNNB1 Syndrome, with particular emphasis on:
- Developing comprehensive Patient Registry and Natural History Studies - Growing mouse models with gene deletions to understand molecular and functional changes - Defining molecular and functional changes caused by CTNNB1 allele deletion - Developing human-derived neurons to assess molecular changes and treatment effectiveness - Partnering with biotech and pharmaceutical companies to advance treatment development

Eligibility

• Applicants: Academic, government, non-profit or for-profit research entities
• Academic researchers: Must have primary faculty appointment at Instructor level or higher, OR be under mentorship of a PI with faculty appointment
• Suitable for: Junior faculty in early career stages, established investigators entering CTNNB1 research field, investigators in rare genetic disease field seeking pilot study funding

Research Type

CCC seeks to support innovative, high-risk/high-reward research in its early stages

Funding Restrictions

• Indirect Costs Cap: No more than 8% of all grant funds may be allocated toward indirect costs (overhead/F&A costs)

Review Process

• Letters of Intent (LOI) reviewed by Scientific Advisory Board (SAB) and an advocate reviewer
• Approved LOIs invited to submit full grant proposal
• Final funding decisions based on: Scientific merit, relevance to CTNNB1 Syndrome, funding levels, and alignment with CCC programmatic goals

Contact Information

• Email: research@curectnnb1.org
• Organization Address: 221 W 9th St Ste 421, Wilmington, DE 19801
• EIN: 83-4541448